Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:49:42.882Z.
Calculation as of: 2026-10-06T19:49:42.882Z.
Quote observation: 2026-10-06T19:45:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d5cf33dffe9efe5aedd0b9249044aa6ff6bda4d300b25a987f268f0e56c28a6c
PE RATIO
N/A
Market Cap
$1.44B
PE Ratio
12.31
TTM Avg
30.95
3Y Avg
30.73
5Y Avg
31.04
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.40B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 44.42 | 39.73 | 39.80 | 78.59 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 8.91 | 9.41 | 9.41 | 62.32 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.36B | N/A | 0.13 | 0.13 | 0.13 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 12.31 | 30.95 | 30.73 | 31.04 |
| Certara, Inc. (CERT)vs › | $1.45B | N/A | 174.30 | 183.89 | 183.89 |
| Omeros Corporation (OMER)vs › | $1.35B | 10.81 | 10.02 | 9.28 | 5.37 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.38
Forward EPS (Est.)
$-0.50
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
